white → orange1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
25D-NBOMe
2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
2C-D-NBOMe, NBOMe-2C-D, Divination, N-Bomb
25D-NBOMe is a synthetic psychedelic of the substituted phenethylamine classcitation needed, derived from 2C-D through the addition of an N-benzyl methoxy group. It was discovered in 2003 by Ralf Heim at the Free University of Berlin and emerged as a recreational substance around 2010 through online research chemical vendors. It acts as a potent partial agonist at the 5-HT2A receptor, producing primarily visual and stimulating effects with roughly sixteen-fold greater potency than its parent compound.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~100 μg
Light100-500 μg
Moderate500-1000 μg
Strong1000-1200 μg
Heavy1200+ μg
Users typically experience a pronounced metallic taste and numbness in the mouth that may persist for up to an hour. Doses in the heavy range present a serious risk of overdose and have been associated with deaths.
Duration
Onset20-40 minutes
Peak1-2 hours
Offset1-2 hours
After Effects6-24 hours
Total4-6 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
The physical effects of 25D-NBOMe can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of 25D-NBOMe are remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout moderate to high doses. At heavy doses, however, mild cognitive alterations become present; this dose seems to be lower in proportion to physical effects when compared to 25I-NBOMe.
Visual
Enhancements
25D-NBOMe presents a mild array of possible visual enhancements.
Geometry
The visual geometry that is present throughout this trip is often described as very similar in appearance to that of DOM. It can be comprehensively described as smooth and organic in style, simple in complexity, fine and zoomed out in detail, slow and fluid in motion, structured in shape, colourful in scheme, bright in colour, and rounded across its corners. In terms of its behaviour, 25D-NBOMe's geometry leads onto level 8A visual geometry with level 8B remaining so far unconfirmed within this substance. It also seems to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelopes the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of physical size attributed to it.
Hallucinatory States
25D-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently within doses higher than of 2mg.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
25D-NBOMe acts as a partial agonist at serotonin 5-HT2A receptors, with broader activity reported across the 5-HT2 receptor family.citation needed The N-benzylmethoxy (NBOMe) substitution confers approximately sixteen-fold greater potency relative to its parent compound 2C-D. Rodent studies have also found that 25D-NBOMe increases dopaminergic signaling in the nucleus accumbens.1
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of 25D-NBOMe and the metabolism of 25D-NBOMe is unknown.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Develops immediately after use.
Cross Tolerance
Serotonergic psychedelics
Baseline Reset
Approximately 2-3 weeks for tolerance to fully reset after a single experience.
Harm Potential
Addiction & Dependence
Psychological
LowWhile formal studies are lacking, 25D-NBOMe appears to have self-regulating qualities due to rapid tolerance buildup lasting 2-3 weeks, which makes compulsive use difficult. However, animal studies have demonstrated reinforcing effects including conditioned place preference, self-administration, and increased dopaminergic signaling in the nucleus accumbens.citation needed
Toxicity
Cardiovascular
Acute cardiovascular stress including elevated blood pressure, tachycardia, abnormal heartbeat, and significant vasoconstriction occurs during intoxication;citation needed at overdose levels, these effects can become dangerous and may progress to cardiac arrest.
Psychosis Risk
Anxiety and paranoia occur more readily than with many classical psychedelics, possibly due to prominent stimulating properties. Overdose can produce confusion, delusions, panic attacks, and aggressive behavior. Feelings of impending doom may occur during comedowns or at high doses.
Seizure Risk
NBOMes are known to cause seizures and have shown a tendency to cause severe seizures.citation needed Overdose is often accompanied by seizures. The unpredictable dose-response relationship increases seizure risk at doses that might otherwise be considered within normal range.
History & Culture
25D-NBOMe is a derivative of the phenethylamine psychedelic 2C-D, created through the addition of an N-benzyl methoxy group to the parent compound. The substance emerged on the designer drug market around 2010, appearing for sale online before formal scientific characterization had been…
Legality
International
25D-NBOMe is not listed under the 1961 Single Convention on Narcotic Drugs. It is not listed under the 1971 Convention on Psychotropic Substances. It is not listed under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
By Country
Illegal14
AustraliaIllegalTherapeutic Goods (Poisons Standard—June 2026) Instrument 20262
25D-NBOMe is captured in Schedule 9 as a substance structurally derived from methoxy-phenylethylamine. Schedule 9 classifies prohibited substances whose manufacture, possession, supply and use should be prohibited by law, except for approved medical or scientific research and analytical, teaching or training purposes; implementation varies between the states and territories.
BrazilIllegal25D-NBOMe is listed in Lista F2, Brazil's list of prohibited psychotropic substances. Brazil's Drug Law prohibits, without authorization or contrary to legal or regulatory rules, producing, importing, exporting, selling, transporting, possessing, or supplying controlled drugs; the applicable schedule is Annex I to SVS/MS Ordinance No. 344/1998 as updated by ANVISA.
ChinaIllegalAnnouncement on the Classification and Control of Non-medical-use Narcotic Drugs and Psychotropic Substances9
Designated as a controlled substance as of October 2015.
FranceIllegal (analog/blanket ban)Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants, annexe IV11
France classifies as narcotics every phenethylamine-derived molecule substituted on the phenyl ring, subject to the exceptions in the schedule. 25D-NBOMe is a substituted phenethylamine and is covered by that blanket classification. Its unauthorised possession, production, and supply are subject to the French narcotics-control regime.
LatviaIllegalCabinet Regulation No. 847, Regulations Regarding Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia18
Classified as a Schedule I controlled substance under national drug legislation.
NetherlandsIllegal (analog/blanket ban)25D-NBOMe is prohibited in the Netherlands as a substance derived from 2-phenethylamine under List IA of the Opium Act. Its 2-phenethylamine structure, substituted phenyl ring, and N-(2-methoxybenzyl) substituent fall within the List IA structural definition. The prohibition has applied since 1 July 2025 and covers import, export, preparation, processing, sale, supply, transport, possession, and manufacture, subject to the statutory exemptions.
NorwayIllegal25D-NBOMe is a narcotic drug in Norway under the Narcotics Regulation (Forskrift om narkotika). The regulation's Appendix I expressly lists 2C-D-NBOMe, the alternative name for 25D-NBOMe, and the listed substances are treated as narcotics. Unauthorised possession, manufacture, importation, exportation, acquisition, sale, and transfer of narcotics are prohibited under Norway's narcotics-control framework.
PolandIllegalRozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (tekst jednolity: Dz. U. 2024 poz. 1139)2324
25D-NBOMe is listed as a psychotropic substance in Group I-P under the Minister of Health regulation. Under the Act on Counteracting Drug Addiction, unauthorised possession, manufacture, and trade in psychotropic substances are criminally controlled.
South KoreaIllegal25D-NBOMe is a psychotropic drug listed in Schedule 3 of the Narcotics Control Act Enforcement Decree. The listing identifies it as 25디-엔비오엠이 (25D-NBOMe) and gives its chemical name as 2-(2,5-dimethoxy-4-methylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. As a scheduled psychotropic drug, its manufacture, possession, use, import, export, sale, and other handling are prohibited except as authorized under the Narcotics Control Act.
SwitzerlandIllegalNarcotics List Ordinance, List E29
Specifically named as a controlled substance under Verzeichnis E of the Swiss narcotics scheduling system.
TurkeyIllegalLaw No. 2313 on the Control of Narcotic Substances, as applied to 25D-NBOMe by Council of Ministers Decision No. 2013/5742 (Annex-2; decision dated 16 December 2013, published in Official Gazette No. 28893 on 25 January 2014); Turkish Penal Code No. 5237, Articles 188 and 191 for trafficking/production/import/export and use or possession-for-use offenses.3031323334
Annex-2 to Decision No. 2013/5742 identifies 25D-NBOMe as 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine. The Early Warning System remains the mechanism for bringing new psychoactive substances under Law No. 2313, and generic classification covers many synthetic derivatives before entry. By 31 December 2021, 971 NPS had been included under Law No. 2313. Penalty application depends on the conduct and facts. A half-rate rule applies to specified synthetic cathinone, synthetic opioid, and amphetamine derivatives, but 25D-NBOMe is not classified under those categories, so they provide no basis for a reduction for 25D-NBOMe.
Controlled / restricted5
United StatesRestrictedFederal Controlled Substances Act, 21 U.S.C. §§ 802(32), 813, 841 and 844; 21 CFR § 1308.11(d) (Schedule I); DEA Diversion Control Division Controlled Substance Schedules and August 2026 Orange Book; North Carolina General Statutes §§ 90-89(6), 90-95; Florida Statutes §§ 893.03(1)(a), (1)(c)193(s), 893.13; and Texas Health and Safety Code §§ 481.1021, 481.1121 and 481.1151.38394041424344454647484950
25D-NBOMe is expressly named in current North Carolina and Florida schedules and is placed in Texas Penalty Group 1-A. Federal primary materials do not expressly list 25D-NBOMe, but DEA warns that its lists are non-comprehensive and that an unlisted substance may be treated as an analogue. Whether federal analogue provisions apply depends on statutory predicates and facts concerning human consumption, which cannot be resolved from the name alone. Direct controls in North Carolina, Florida, and Texas coexist with unresolved federal and nationwide state-law scope, and the compound's lawfulness in other U.S. states is not established.
AustriaRestrictedNeue-Psychoaktive-Substanzen-Gesetz, Anlage I3
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
FinlandRestrictedGovernment Decree on Psychoactive Substances Banned from the Consumer Market10
Listed in the government decree on prohibited psychoactive substances in consumer markets.
GermanyRestricted25D-NBOMe is covered by Anlage 1 of Germany’s Neue-psychoaktive-Stoffe-Gesetz (NpSG) as a 2-phenethylamine-derived compound, a defined substance group encompassing its 2C-D scaffold and N-(2-methoxybenzyl) substitution. Under the current consolidated NpSG, last amended on 7 January 2026, section 3 prohibits trading, placing on the market, manufacturing, import, export, acquisition, possession, and administering covered substances to another person; section 4 criminalizes specified commercial, supply, manufacture, and import violations.
JapanRestrictedMinisterial Ordinance Designating Substances under the Pharmaceuticals and Medical Devices Act17
Designated as a controlled substance effective March 25, 2015.
References
Source Pages
Citations
- Jae-Gyeong Lee, Kwang-Hyun Hur, Su-Bin Hwang, Sooyeun Lee, Seok-Yong Lee, & Choon-Gon Jang. (August 2023). Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System. ACS Chem Neurosci, 14(15), 2658–2666. https://doi.org/10.1021/acschemneuro.3c001961
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/asmade/2026-05-01/text/original/pdf1
- Neue-Psychoaktive-Substanzen-Gesetz, Anlage I. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200093801
- ANVISA RDC No. 970 of 19 March 2025, updating Annex I to SVS/MS Ordinance No. 344/1998. gov.br (n.d.). https://www.gov.br/anvisa/en/rules-and-regulations/arquivos/rdc-970-2025-e.pdf1
- ANVISA RDC No. 970 of 19 March 2025, updating Annex I to SVS/MS Ordinance No. 344/1998. gov.br (n.d.). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- ANVISA RDC No. 970 of 19 March 2025, updating Annex I to SVS/MS Ordinance No. 344/1998. planalto.gov.br (n.d.). https://www.planalto.gov.br/ccivil_03/_ato2004-2006/2006/lei/l11343.htm1
- Controlled Drugs and Substances Act, Schedule III. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/FullText.html1
- Order Amending Schedule III to the Controlled Drugs and Substances Act (2C-phenethylamines), SOR/2016-73. (n.d.). https://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors73-eng.html1
- Announcement on the Classification and Control of Non-medical-use Narcotic Drugs and Psychotropic Substances. gov.cn (n.d.). https://www.gov.cn/xinwen/2015-10/01/content_2941700.htm1
- Government Decree on Psychoactive Substances Banned from the Consumer Market. finlex.fi (n.d.). https://www.finlex.fi/fi/laki/ajantasa/2014/201411301
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
2 August 2026
Lyrea · Updated the article
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25D-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.